Zacks: Brokerages Expect TherapeuticsMD, Inc. (NASDAQ:TXMD) to Post -$0.10 EPS

Wall Street analysts predict that TherapeuticsMD, Inc. (NASDAQ:TXMD) will post earnings per share of ($0.10) for the current quarter, Zacks reports. Three analysts have made estimates for TherapeuticsMD’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.11). TherapeuticsMD reported earnings per share of ($0.19) in the same quarter last year, which indicates a positive year-over-year growth rate of 47.4%. The company is expected to issue its next earnings report on Thursday, February 18th.

According to Zacks, analysts expect that TherapeuticsMD will report full year earnings of ($0.62) per share for the current financial year, with EPS estimates ranging from ($0.63) to ($0.57). For the next financial year, analysts forecast that the firm will post earnings of ($0.37) per share, with EPS estimates ranging from ($0.54) to ($0.21). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for TherapeuticsMD.

Get TherapeuticsMD alerts:

A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of TherapeuticsMD in a research note on Tuesday, November 10th. Zacks Investment Research upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Friday, November 13th. Finally, HC Wainwright dropped their target price on shares of TherapeuticsMD from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, January 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $6.29.

A number of large investors have recently modified their holdings of the business. Victory Capital Management Inc. grew its holdings in TherapeuticsMD by 18.9% during the 4th quarter. Victory Capital Management Inc. now owns 40,677 shares of the company’s stock worth $49,000 after acquiring an additional 6,479 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in TherapeuticsMD by 60.1% during the 4th quarter. Teacher Retirement System of Texas now owns 22,488 shares of the company’s stock worth $27,000 after acquiring an additional 8,441 shares during the last quarter. American International Group Inc. grew its holdings in TherapeuticsMD by 6.0% during the 4th quarter. American International Group Inc. now owns 149,737 shares of the company’s stock worth $181,000 after acquiring an additional 8,476 shares during the last quarter. Stoneridge Investment Partners LLC grew its holdings in TherapeuticsMD by 48.3% during the 3rd quarter. Stoneridge Investment Partners LLC now owns 37,544 shares of the company’s stock worth $59,000 after acquiring an additional 12,220 shares during the last quarter. Finally, California State Teachers Retirement System grew its holdings in TherapeuticsMD by 4.4% during the 3rd quarter. California State Teachers Retirement System now owns 357,178 shares of the company’s stock worth $564,000 after acquiring an additional 14,993 shares during the last quarter. 52.56% of the stock is currently owned by hedge funds and other institutional investors.

Shares of TXMD stock traded down $0.12 during mid-day trading on Tuesday, reaching $1.58. The company’s stock had a trading volume of 409,752 shares, compared to its average volume of 15,857,688. TherapeuticsMD has a 1-year low of $0.85 and a 1-year high of $2.75. The company has a market cap of $472.13 million, a P/E ratio of -2.25 and a beta of 2.19. The firm’s 50-day moving average is $1.64 and its two-hundred day moving average is $1.46.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.

See Also: Using the New Google Finance Tool

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.